期刊文献+

不同剂型美托洛尔对慢性收缩性心力衰竭心率变异性的影响 被引量:6

Effects of metoprolol of different drug forms on heart rate variability in patients with chronic congestive heart failure
原文传递
导出
摘要 目的探讨不同剂型美托洛尔对慢性收缩性心力衰竭(CHF)心率变异性(HRV)的影响。方法 60例CHF患者被随机分为平片组及缓释片组,在常规抗心衰治疗基础上,分别服用美托洛尔平片和缓释片;从小剂量开始,逐步增加剂量,连续6个月。观察治疗前后HRV、左室射血分数(LVEF)、病死率及因心衰加重住院情况。结果治疗后LVEF两组均略增加。观察期间在病死率、再住院率方面两组间差异均无统计学意义(P>0.05);但在缓释片组因心衰加重再住院有减少趋势。两组治疗后HRV指标均明显改善,缓释片组优于平片组(P<0.05)。结论美托洛尔缓释片较平片明显改善CHF患者HRV。 Objective To compare the therapeutic efficacy of two drug forms of metoprolol on heart rate variability(HRV)in patients with chronic congestive heart failure(CHF).Methods Sixty patients with CHF were randomly divided into two groups with 30 cases each.The patients took the immediate-release metoprolol(group IRM)or sustainded-release metoprolol(group SRM),which started with the low dosage and then increased gradually for continuous 6 months.The changes of HRV were observed by ambulatory electrocardiogram(ECG)before and 6 mouths after treatment.Left ventricular ejection fraction(LVEF),mortality and readmission rate secondary to heart failure were observed.Results After treatment,LVEF was increased slightly in both groups.There were no significant differences in the mortality and readmission rates in both groups(P0.05).But there was a tendency of decreased readmission rate secondary to heart failure in group SRM.The improvements of HRV parameters were better in group SRM than those in group IRM(P0.05).ConclusionSustainded-release metoprolol is better than immediate-release metoprolol in improving HRV in patients with CHF.
出处 《江苏医药》 CAS CSCD 北大核心 2010年第17期2024-2026,共3页 Jiangsu Medical Journal
关键词 美托洛尔 慢性心力衰竭 心率变异性 Metoprolol Chronic congestive heart failure Heart rate variability
  • 相关文献

参考文献9

  • 1慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2413
  • 2无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3662
  • 3Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in adults:a report of the american college of cardiology foundation/ american heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation[J]. J Am Coil Cardiol, 2009,53 (15) : e1-e90.
  • 4Dickstein K, Cohen-solai A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)[J]. Eur Heart J, 2008,29 (19) : 2388-2442.
  • 5Hjalmarson A,Goldstein S,Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) [J]. JAMA, 2000,283 (10) : 1295-1302.
  • 6Guzzetti S, La Rovere MT,Pinna GD, et al. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure[J]. Eur Heart J, 2005,26 (4):357-362.
  • 7La Rovere MT,Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients[J]. Circulation, 2003,107 (4):565- 570.
  • 8Abrahamsson B, Lueker P, Olofsson B, et al. The relationship between metoprolol plasma concentration and betal-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations[J]. J Clin Pharmaeol, 1990,30(2 Suppl) :S46-54.
  • 9Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET).. randomised controlled trial[J]. Lancet, 2003,362 (1) : 7-13.

二级参考文献43

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 2Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 3Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 4Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 5Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 6Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 7Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.
  • 8Enright PL, Sherrill DL Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med, 1998, 158(5 pt 1) :1384-1387.
  • 9Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J, 1999, 14(2) : 270-274.
  • 10Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation, 2002, 105 (20):2328-2331.

共引文献5957

同被引文献51

  • 1于晓燕,赵盈,吴杰,张磊.美托洛尔治疗慢性收缩性心衰临床观察[J].山东医药,2004,44(31):24-25. 被引量:1
  • 2陈鲁原.治疗高血压的联合用药,应以钙拮抗剂为基础[J].循证医学,2006,6(3):129-130. 被引量:5
  • 3范萌,赵晔,魏锋.机械瓣膜置换术后口服华法林抗凝治疗的相关问题探讨[J].中国医药导报,2007,4(04X):149-150. 被引量:1
  • 4叶任高,陆再英.内科学[M].7版.北京:人民卫生出版社,2008:91-93.
  • 5Kors JA,Swenne CA,Greise KH,et al.Cardiovasculardisease,riak factors,and heart rate variability in the generalpopulation[J].J Electrocardiol,2007,40(1):19-21.
  • 6Guzzetti S,La Rovere MT,Pinna GD,et al.Different spectralcomponents of 24h heart rat e variability are related todifferent modes of death in chronic heart failure[J].Eur HeartJ,2005,26(4):357-362.
  • 7La Rovere MT,Pinna GD,Maestri R,et al.Short-term heartrate variability strongly predicts sudden cardiac death in chronicheart failure patients[J].Circulation,2003,107(4):565-570.
  • 8Hunt SA,Abraham WT,Chin MH,et al.2009Focused updateincorporated into the ACC/AHA 2005 Guidelines for thediagnosis and management of heart failure in adults:a reportof the american college of cardiology foundation/americanheart association task force on practice guidelines developed incollaboration with the international society for heart and lungtransplantation[J].J Am Coll Cardiol,2009,53(15):e1-e90.
  • 9Dickstein K,Cohen Solal A,Filippatos G,et al.ESC Guidelinesfor the diagnosis and treatment of acute and chronic heartfailure 2008:the Task Force for the Diagnosis and Treatmentof acute and chronic heart failure 2008of the European Societyof Cardiology.Developed in collaboration with the HeartFailure Association of the ESC(HFA)and endorsed by theEuropean Society of Intensive Care Medicine(ESICM)[J].Eur Heart J,2008,29(19):2388-2442.
  • 10Singh JP,Larson MG,Tsuji H,et al.Reduced heart rate varia-bility and new-onset hypertension:insights into pathogenesisof hypertension:the Framingham Heart Study[J].Hyperten-sion,1998,32(2):293-297.

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部